Biotechnology
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developinga proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

$7.5M

Market Cap • 12/25/2024

2021

(3 years)
Founded

2022

(2 years ago)
IPO

NASDAQ

Listing Exchange
Flag of GB

London

Headquarters